Clinical trials: IgAN
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.
Immunoglobulin A Nephropathy
A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.
- Trial name
- NCT06952426
- Testing
- No intervention, Other treatment, Iptacopan
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy (IgAN)
A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy
This is a Phase II, multicenter, open-label study. Eligible subjects who have completed the HSK39297-202 study will be enrolled.Starting dose is 200 mg QD.Dose may be increased to 300 mg QD after 8-12 weeks of stable 200 mg QD…
- Trial name
- NCT07616700
- Testing
- HSK39297 200mgQD, HSK39297 300mgQD
- Where
- 2 sites in China
- Volunteers
- 73 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Immunoglobulin A (IgA) Nephropathy
Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy
Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN
- Trial name
- IGNAZ (NCT05065970)
- Testing
- Felzartamab
- Where
- 59 sites in United States, Australia and 13 more
- Volunteers
- 54 people
- Sponsor
- HI-Bio, A Biogen Company
IgA Nephropathy
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
This open-label Phase 2 study will characterize the safety and efficacy of JADE101 in participants with IgA nephropathy, and the results will contribute to the overall clinical characterization of JADE101 in this patient…
- Trial name
- NCT07541287
- Testing
- JADE101
- Where
- 22 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Jade Biosciences, Inc.
IgA Nephropathy (IgAN)
A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy
This Phase 3 study will evaluate the safety and efficacy of JADE101 compared with placebo in adults with immunoglobulin A nephropathy (IgAN).
- Trial name
- NCT07902817
- Testing
- JADE101
- Where
- 4 sites in United States
- Volunteers
- 480 people
- Sponsor
- Jade Biosciences, Inc.
IgA Nephropathy (IgAN)
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
Efficacy and safety of MY008211A in IgAN patients
- Trial name
- NCT06687174
- Testing
- MY008211A tablets
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd
IgA Nephropathy (IgAN), Berger Disease
Monthly Dosing of Atacicept in IgAN
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
- Trial name
- NCT07020923
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Vera Therapeutics, Inc.
IgA Nephropathy, Membranous Nephropathy
IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients
IM19 CAR-T cell therapy for IgA nephropathy patients with urinary protein and renal dysfunction, as well as patients with intermediate to high-risk primary membranous nephropathy
- Trial name
- NCT06690359
- Testing
- IM19 chimeric antigen receptor T cell injection
- Volunteers
- 12 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Immunoglobulin A Nephropathy
A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe
The purpose of this study is to evaluate participant treatment experience with Povetacicept injection administered via autoinjector relative to Sibeprenlimab injection administered via prefilled syringe (PFS), and to assess the…
- Trial name
- NCT07890909
- Testing
- Povetacicept, Sibeprenlimab
- Volunteers
- 40 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Immunoglobulin A Nephropathy (IgAN)
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.
- Trial name
- SHIFT (NCT07146906)
- Testing
- zigakibart
- Where
- 30 sites in United States, Brazil and 9 more
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy
A Phase IIa Study in Primary IgA Nephropathy Patients
This is a phase IIa, multicenter, single-arm, open-label study to evaluate the safety and efficacy of XH-S003 in patients with primary IgA nephropathy
- Trial name
- NCT07634744
- Testing
- XH-S003 Capsule
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Primary IgA Nephropathy; Autoimmune Hepatitis
Relative Bioavailability Study of HR19042 in Healthy Subjects
This is a single-center, randomized, open-label, three-period, dual Latin square crossover study. Primary Objective： 1. To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release…
- Trial name
- NCT06922305
- Testing
- HR19042 Capsule, Tarpeyo®, Budenofalk®
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
IgA Nephropathy, Immunoglobulin A Nephropathy
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
The ASSIST study was a phase 2, double-blind, placebo-controlled crossover study to evaluate the safety and efficacy of atrasentan vs.
- Trial name
- ASSIST (NCT05834738)
- Testing
- Atrasentan
- Where
- 30 sites in United States, Australia and 4 more
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy
Managed Access Programs for EXV811, Atrasentan
The purpose of this registration is to list Managed Access Programs (MAPs) related to EXV811, Atrasentan
- Trial name
- NCT07319585
- Testing
- Atrasentan
- Sponsor
- Novartis Pharmaceuticals
Primary IgAN
FXS6837 for the Treatment for IgAN Patients（Longterm Study）
This is a multicenter, open-label study to evaluate the long-term safety and efficacy of FXS6837 capsules in primary IgAN patients.
- Trial name
- NCT07750665
- Testing
- FXS6837 Capsule
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Immunoglobulin A Nephropathy
A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being…
- Trial name
- SPARTACUS (NCT05856760)
- Testing
- Sparsentan
- Where
- 30 sites in United States, Hong Kong
- Volunteers
- 48 people
- Sponsor
- Travere Therapeutics, Inc.
IgA Nephropathy
Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN)
This Phase 3, open-label study will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of sibeprenlimab administered subcutaneously every 4 weeks in pediatric…
- Trial name
- NCT07770815
- Testing
- Sibeprenlimab, Standard of care
- Volunteers
- 24 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
IGA Nephropathy
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
Phase 2, multi-center, open label extension study to evaluate 2 dose regimens of fostamatinib in approximately 25 subjects. The study will consist of 11 visits over 15 months.
- Trial name
- NCT02433236
- Testing
- Fostamatinib Disodium tablet 100 mg, Fostamatinib Disodium tablet 150 mg
- Sponsor
- Rigel Pharmaceuticals
Immunoglobulin a Nephropathy
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
This study will evaluate the efficacy and safety of HS-10390 in subjects with primary IgA nephropathy, and explore the optimal dose for the treatment.
- Trial name
- NCT06635772
- Testing
- HS-10390, Irbesartan
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hansoh BioMedical R&D Company